United States Patent 6,561,976: scope, claim-by-claim boundaries, and US patent landscape for teratogenic drug distribution systems (thalidomide REMS-style controls)

Executive summary: US Patent 6,561,976 claims a US patient-and-prescriber distribution workflow for teratogenic drugs that (i) registers prescribers and patients in a computer-readable system, (ii) provides teratogenic-risk counseling and obtains informed consent, (iii) determines pregnancy status and pregnancy capability, (iv) blocks access unless the patient is not currently pregnant (or is incapable of becoming pregnant), and (v) for refill cycles, obtains additional pregnancy-relevant information and triggers pregnancy testing when risk of pregnancy in the prior ~28 days exists. Dependent claims tightly align with thalidomide and operational constraints (not more than ~28-day prescriptions; pregnancy-test gating before refills; contraception counseling; providing contraceptive devices/formulations). The patent is method-focused and system-logic driven; it does not claim a formulation, composition, or specific manufacturing process. In practice, its claim scope maps closely to thalidomide REMS-style controls (prescriber/patient enrollment plus pregnancy testing, contraception counseling, and short-cycle dispensing), which raises both infringement risk for systems that implement similar gates and validity risk if later regulatory frameworks render parts of the claimed workflow broadly obvious or already disclosed.

What does US patent 6,561,976 claim for distributing teratogenic drugs to prevent fetal exposure?

Core independent claim logic (Claims 1 and 8): both independent claims are directed to a “method for distributing a teratogenic drug” with a computer-readable registration and verification system that prevents fetal exposure by gating dispensing on pregnancy status determinations.

Claim 1 (physician registration + patient counseling + pregnancy gating + dispensing unlock)

Claim 1 recites a sequence:

Register physicians permitted to prescribe in a computer-readable storage medium.
Provide counseling information on teratogenic risks attendant to fetal exposure.
Obtain informed consent to receive the drug despite risks.
Register the patient with information on whether the patient can become pregnant or impregnate.
If capable of becoming pregnant: determine the patient is not currently pregnant and register that.
Permit access only after consulting the system to verify the patient is either:
- incapable of becoming pregnant, or
- not currently pregnant.

Claim 1 scope posture: broad on system architecture (generic “computer-readable storage medium”) and broad on how pregnancy is determined (no specific test method required in Claim 1 itself), while still requiring a specific gating outcome: access only after verification of “incapable or not currently pregnant.”

Claim 8 (pharmacy fulfillment eligibility rules + pregnancy prevention constraints embedded in eligibility)

Claim 8 repeats the physician registration, counseling, consent, patient registration, pregnancy determination, and gating steps, but its independent “structure” shifts by integrating the eligibility determination into the “permit access only after verifying” language.

Net effect: Claim 8 is substantively similar to Claim 1, with slightly different phrasing but the same functional blocks: prescriber registration, counseling/consent, patient enrollment with pregnancy capability, pregnancy status confirmation, and dispensing lock.

Claim 15 (eligibility definition + operational dispensing timing constraints)

Claim 15 adds an “eligibility to receive” definition for a female patient and is the most operationally constrained claim set. It includes:

Authorize one or more pharmacies to fulfill prescriptions only after confirming eligibility.
Register physicians authorized to prescribe in the computer medium.
Register the patient in the medium.
Deem patient “eligible” only if the following are satisfied:
1. Counseling + informed consent to receive despite danger of exposing a fetus.
2. At least two forms of birth control for at least about 4 weeks prior to initiation and throughout treatment.
3. Negative pregnancy testing for:
  - the month before, and
  - each month during treatment.
4. Prescription size/timing:
  - no more than about 28 days supply,
  - prescription written no more than about 7 days prior to being presented for fulfillment.

Claim 15 scope posture: narrower than Claims 1/8 because it locks in a multi-part eligibility checklist including contraception duration/frequency, pregnancy testing cadence, and dispensing timing windows.

What parts of the claims are likely to matter most for infringement?

1) The “computer-readable storage medium” and verification consult step

Claims 1 and 8 require registration and that dispensing is permitted only after “consulting”/“verifying” in the system. If a distribution workflow is implemented purely on paper or by static checklists not tied to a computer-readable registration medium that is queried at dispensing time, it is outside the express steps.

2) Counseling + informed consent

Every independent claim (via recitals) includes counseling and informed consent. Systems that dispense without documented informed consent steps, or that treat counseling as optional, would fall outside the explicit claim workflow.

3) Pregnancy capability registration + current pregnancy status gating

Claim 1’s step (d)-(f) hinges on:

capturing whether the patient is capable of becoming pregnant, and
for those capable, determining the patient is not currently pregnant,
then permitting access only after verifying incapability or “not currently pregnant.”

4) Refill cycle augmentation: pregnancy-risk re-assessment and triggered testing

Claims 5-6 (dependent on Claim 3) add refill-specific controls:

Prescription is for no more than about 28 days (Claim 4 or Claim 11).
Before refill: obtain additional information about likelihood the patient became pregnant during the previous 28 days, and:
- if could have become pregnant, administer a pregnancy test to verify not currently pregnant before refilling.

This is a key limitation because it ties an intermediate “risk assessment” step to the decision to administer a pregnancy test at refill time.

5) Contraception counseling and contraceptive device/formulation

Claims 6-7 and 13-14 require contraception counseling and, optionally, providing contraceptive device or formulation. These are narrower “add-ons,” but they can matter for design-around: a program that only documents contraceptive counseling but does not provide contraceptives could avoid dependent claim coverage (though it could still infringe Claims 1/8 if the counseling/consent/pregnancy gating steps are otherwise implemented).

Which dependent claim limits narrow coverage the most?

Claim	Key limiting feature	Practical design impact
2, 9, 16	Drug is thalidomide	Narrows method to thalidomide-specific distribution programs. If not thalidomide, these dependents drop away.
3, 10	Access provided via prescription	Excludes direct dispensing models not involving prescriptions.
4, 11	Prescription no more than ~28 days	Excludes longer-cycle dispensing.
5, 12	Refill triggers: risk info for prior ~28 days + pregnancy test before refill if risk exists	Excludes refill workflows that test on a fixed cadence regardless of risk info, or that dispense without refill gating tests.
6, 13	Adds contraception counseling	Narrow add-on layer.
7, 14	Adds providing contraceptive device/formulation	Further narrows system if product provides/dispenses contraceptives.
15	Eligibility checklist: two forms of birth control for ~4 weeks, monthly pregnancy tests, ~28-day supply, prescription written within ~7 days	Most constrained, likely closest to thalidomide programs, but also easiest to design around by changing cadence or eligibility steps.

What is the likely “scope” of claim terms like “teratogenic drug” and “computer readable storage medium”?

“Teratogenic drug”

The claims are not limited to thalidomide in the independent claims. The “teratogenic” classification is the trigger category; it captures drugs where fetal exposure risk is teratogenic. For thalidomide, dependent claims expressly anchor the scope (Claims 2, 9, 16), which likely reflect the patent’s prosecution and commercial focus.

“Computer readable storage medium”

The claims do not require a specific database type, UI, or interface. The limitation is functional: a medium that stores the relevant prescriber and patient data and is consulted at dispensing to verify eligibility. A program that uses any electronic registration or access system can satisfy this if it is the basis for “consulting” and “verifying” pregnancy status at dispensing time.

What US patent landscape surrounds 6,561,976 for teratogenic drug REMS-like distribution?

Business-relevant takeaway: US 6,561,976 is likely best viewed as an early, method-and-workflow protection around REMS-style pregnancy prevention controls. Thalidomide has long been associated with pregnancy prevention requirements, including prescriber/patient enrollment, contraception counseling, and pregnancy testing tied to dispensing.

How these claims align with downstream regulatory structures

Even without relying on later case law, the claim mechanics map closely to common regulatory program elements for teratogenic medicines:

Prescriber enrollment/authorization
Patient enrollment
Counseling and informed consent
Pregnancy testing cadence
Contraception counseling and contraception use requirements
Dispensing limited to short supply windows

This alignment is actionable for:

freedom-to-operate (FTO) designs for any thalidomide or thalidomide analog distribution workflow in the US, and
litigation positioning on whether similar programs are within or outside the claimed workflow steps.

Litigation and “landscape” analysis constraints

A full landscape typically requires patent-family mapping, assignees, priority data, and citations, plus Orange Book and Paragraph IV filings tied to specific thalidomide products. Those identifiers are not present in the input. Without them, only the claim-scope-to-regulatory-mechanism mapping can be stated with precision.

When does US 6,561,976 lose exclusivity?

No timing data provided in the input. Without priority/filing/issuance and any applicable terminal disclaimer, PTA, or continuation chain details, an accurate exclusivity/expiration timeline cannot be produced.

What formulations or administration routes does US 6,561,976 cover?

None. The patent is not directed to a composition, formulation, or method of manufacture. It is directed to a distribution/dispensing workflow that prevents fetal exposure, with thalidomide named only in dependent claims.

What generic entry risks exist for methods that implement similar pregnancy gating?

Because the claims are method claims, entry risk is not tied only to whether a generic drug product uses the same formulation. Risk is tied to whether the generic (or any distributor/pharmacy program) implements a workflow that includes:

physician registration in a computer-readable medium,
patient counseling and informed consent,
pregnancy capability and current pregnancy status enrollment/verification,
dispensing access only when “incapable or not currently pregnant”,
short-fill prescriptions (dependent claim limitation),
and refill gating with risk assessment and pregnancy testing (dependent claim limitation).

A generic entering the market could still avoid infringement if it uses a materially different workflow that does not include the claimed steps or timing gates.

How strong is the patent estate for US 6,561,976 based on claim structure?

Claim structure strength factors:

Concrete process steps (registration, counseling/consent, verification gates) can be enforced against systems that replicate the workflow.
Computer-medium dependency can narrow enforceability against non-electronic processes.
Dependent claim limits (thalidomide-only, 28-day fill limits, refill pregnancy testing conditional on risk info, two-contraception and monthly testing cadence, prescription issuance timing) constrain coverage to particular operational designs.

Key practical enforcement lever: If the patentee can show a US distribution program that tracks each element, infringement exposure is straightforward. If programs differ in prescription fill windows, pregnancy test cadence, or the trigger logic for testing at refill, dependent claim coverage may be harder to prove.

How does US 6,561,976 compare with other thalidomide pregnancy prevention systems?

Relative to “system design” controls: US 6,561,976 is a workflow claim rather than a molecular or formulation claim. That makes it comparable to other patents (if any) that claim components of REMS programs:

Some may claim specific enrollment databases or communications logic.
Others may claim particular pharmacy or prescriber workflows.
This patent’s footprint is in the combination: enrollment + counseling/consent + pregnancy capability/status verification + gating dispensing access.

Without a list of other relevant US patents and claims, only the conceptual comparison can be offered: programs that replicate the same gating structure are most exposed.

Key Takeaways

US 6,561,976 protects a method for distributing teratogenic drugs that blocks fetal exposure by requiring electronic enrollment/registration, counseling and informed consent, pregnancy capability and “not currently pregnant” verification, and dispensing access only after verification.
The broadest independent claims (1 and 8) are centered on registration and verification gating, not on specific pregnancy tests or contraception devices.
The narrowest coverage sits in dependent claims and Claim 15: thalidomide-specific distribution, ≤~28-day prescription supply, ≤~7-day prescription writing window, two forms of contraception for ~4 weeks, and monthly pregnancy testing, plus refill-triggered pregnancy testing when pregnancy risk in the prior ~28 days exists.
The infringement focus is on whether a distribution program implements the same step sequence and operational gates, especially at pharmacy fulfillment and refill moments.

FAQs

1) Does US 6,561,976 require a specific type of pregnancy test?
Not in the independent workflow as provided. Dependent claims add pregnancy-testing steps, but the claim language centers on verifying “not currently pregnant” and refill gating rather than mandating a particular assay.

2) Can a non-affirmative contraception program avoid infringement?
Dependent claims that require contraception counseling and contraceptive devices/formulations would be avoided if those steps are not implemented. Independent claims still require counseling and informed consent on teratogenic risk, but contraception counseling/device limits appear in dependent claims.

3) Is thalidomide required for infringement of independent claims?
No. Claims 1 and 8 are directed to “a teratogenic drug.” Thalidomide is explicitly required only in dependent claims (Claims 2, 9, and 16) and not for the independent claim category as provided.

4) What dispensing model design changes are most likely to reduce risk?
Changing electronic registration/verification mechanics, eliminating the “consult the medium to verify” gating step, or materially changing short-supply windows and refill-test trigger logic can move the design outside dependent claim boundaries.

5) Does the patent cover manufacturing or formulation IP?
No. Based on the claims provided, it is limited to a distribution/disbursement workflow intended to prevent fetal exposure.

References

United States Patent 6,561,976 (claims as provided in prompt).

Details for Patent: 6,561,976

Summary for Patent: 6,561,976